CRISPR Tx, Adaptimmune, and Cellectis Report Data in Solid Tumors; AACR 2023 Analysis 1
Here is a brief preview of this blast: AACR 2023 Analysis 1: CRISPR Tx, Adaptimmune, and Cellectis presented data on their CAR-T assets for solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered: